Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...

A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

Normally, filtered glucose is about 125 mg/min. Main action of SGLT2 inhibitors is the induction of glucosuria and osmotic diuresis. SGLT2 inhibitors reduce effectively fasting and postprandial ...

SGLT2 inhibitors are a new family of agents, which occlude the path of SGLT2 glucose reabsorption and cause glucosuria. Efficacy of SGLT2 inhibitors includes reduction of HbA1c, fasting and ...

With studies showing potential for SGLT2 inhibitors in heart failure ... Others were concerned that there was uncertainty about the mechanism. Cost was also a concern raised by cautious ...

Sotagliflozin, a drug for diabetes and kidney disease, offers significant protection against heart attacks and strokes by ...

Use of SGLT2 inhibitors was associated with a lower risk for rhabdomyolysis than DPP-4 inhibitors among statin users. Sodium-glucose cotransporter-2 (SGLT2) inhibitor use is associated with a ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

as it has not been observed in trials of selective SGLT2 inhibitors." "These results demonstrate a new mechanism of action -- combined blockade with sotagliflozin of the SGLT1 receptors found in ...